Deutsche Bank lowered Sanofi’s price target by €5 to €95 while maintaining a Buy rating amid strong Q1 2026 earnings growth.
Deutsche Bank reduced Sanofi’s (NASDAQ:SNY) price target to EUR 95 from EUR 100 on June 15, reaffirming its Buy rating. The adjustment follows Sanofi’s Q1 2026 results, which showed 13.6% sales growth at constant exchange rates and business EPS of €1.88.
Sanofi reported a 49.6% surge in pharma launches sales to €1.2 billion, driven by Ayvakit, ALTUVIIIO, and Sarclisa. Dupixent sales rose 30.8% to €4.2 billion, while vaccine sales grew 2.1% to €1.3 billion. R&D expenses increased 1.5% to €1.7 billion, and selling costs climbed 11.6% to €2.3 billion.
The company’s pharmaceuticals, consumer healthcare, and vaccines segments underpinned the quarter’s performance, though rising expenses offset some gains.